Abbott Clears US Antitrust Hurdle for Ibis Buy | GenomeWeb
NEW YORK (GenomeWeb News) – Abbott today said that it has received clearance from US antitrust regulators to proceed with the acquisition of Isis Pharmaceuticals’ molecular diagnostics subsidiary Ibis Biosciences.
 
The clearance comes less than a week after Abbott said that it had exercised its option to acquire the remaining 81.4 percent stake of Ibis that it didn’t already own for $175 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.